AIA
LCTX icon

AssuredPartners Investment Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

AssuredPartners Investment Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.6K Hold
16,500
– – ﹤0.01% 414
2026
Q1 		$25.4K Hold
16,500
– – ﹤0.01% 402
2025
Q4 		$27.6K Hold
16,500
– – ﹤0.01% 342
2025
Q3 		$27.9K Hold
16,500
– – 0.01% 267
2025
Q2 		$15K Hold
16,500
– – ﹤0.01% 239
2025
Q1 		$7.45K Hold
16,500
– – ﹤0.01% 326
2024
Q4 		$8.29K Buy
+16,500
New +$12.1K ﹤0.01% 320

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

AssuredPartners Investment Advisors's LCTX Position: Q2 2026 in Review

AssuredPartners Investment Advisors held its Lineage Cell Therapeutics (LCTX) position steady in Q2 2026 at 16,500 shares worth $21.6K. The position accounts for ﹤0.01% of the portfolio, ranked #414.

AssuredPartners Investment Advisors first reported a position in LCTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $27.9K in Q3 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • AssuredPartners Investment Advisors held 16,500 shares of Lineage Cell Therapeutics worth $21.6K as of Q2 2026.
  • AssuredPartners Investment Advisors left its Lineage Cell Therapeutics share count unchanged in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of AssuredPartners Investment Advisors's portfolio in Q2 2026, its #414 holding.
  • AssuredPartners Investment Advisors first reported a position in Lineage Cell Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • AssuredPartners Investment Advisors's Lineage Cell Therapeutics position peaked at $27.9K in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on AssuredPartners Investment Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.